Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have announced that Byetta (exenatide) injection has been approved for expanded combination therapy in people with type 2 diabetes who have not achieved adequate blood sugar control on a thiazolidinedione (TZD).
SAN DIEGO—Treatment of type 2 diabetes with metformin alone or in combination with other hypoglycemic agents is associated with decreased all-cause mortality compared with anti-diabetic regimens that do not contain metformin, data suggest.
Adding spironolactone to an ACE inhibitor or angiotensin II receptor blocker (ARB) is associated with a marked and sustained antiproteinuric effect in type 2 diabetics, researchers in the Netherlands found.
PHILADELPHIA—After 15-36 months, diabetics taking thiazolidinediones had increased bone loss at the hip and spine, according to data presented here at the 28th annual meeting of the American Society of Bone and Mineral Resesarch.
As part of an effort by the FDA and the Federal Trade Commission to halt deceptive online advertisements and sales of products misrepresented as diabetes cures or treatments, the agencies have sent approximately 180 letters and advisories to Internet outlets in the United States, Mexico, and Canada.